Choriocarcinoma Metastases

Choriocarcinoma is a rare, fast-growing cancer that starts in the cells that would normally develop into the placenta during pregnancy. When these cancerous cells spread from their original location in the uterus (or, more rarely, in the ovary or testis) to other parts of the body, the condition is called choriocarcinoma metastases. These metastatic tumors maintain the aggressive behavior of the original choriocarcinoma and often cause bleeding and high levels of human chorionic gonadotropin (hCG), a hormone normally made in pregnancy. Metastases most commonly reach the lungs, but they can invade almost any organ through the bloodstream. Early recognition and treatment are critical, as metastatic choriocarcinoma can be life-threatening without prompt chemotherapy and, sometimes, surgery.

Choriocarcinoma is a highly malignant form of gestational trophoblastic neoplasia (GTN) characterized by abnormal proliferation of trophoblastic tissue. When choriocarcinoma spreads beyond the uterus, it most commonly metastasizes to the lungs (60–80%), vagina, brain, liver, and, less frequently, to the kidneys, spleen, or bone. Metastases arise because aggressive trophoblast cells invade blood vessels and disseminate hematogenously. Patients may present with hemoptysis (lung), neurological deficits (brain), abdominal pain or hepatomegaly (liver), and vaginal bleeding or masses (vaginal) emedicine.medscape.comcancer.gov. Early recognition and a coordinated, multidisciplinary approach are crucial for optimizing outcomes.

---

Types of Choriocarcinoma Metastases

1. Gestational Metastatic Choriocarcinoma
   This type arises from a previous pregnancy—whether a full-term birth, miscarriage, or molar pregnancy. The cancer cells carry paternal and maternal genes, making them more sensitive to chemotherapy, and patients often have an excellent prognosis if treated early.

2. Non-Gestational (Germ Cell) Metastatic Choriocarcinoma
   Originating in germ cells of the ovary or testis, this form carries only the patient’s genes. It tends to be more resistant to standard chemotherapy regimens and may require more aggressive or specialized treatment approaches.

3. Mixed Germ Cell Metastases with Choriocarcinoma Elements
   In some ovarian or testicular germ cell tumors, choriocarcinoma cells coexist with other tumor types (e.g., teratoma or embryonal carcinoma). These mixed tumors can metastasize, and their treatment must address every component.

4. Solitary Versus Multiple Metastatic Lesions
   Metastases may present as a single nodule in one organ or as multiple deposits in several organs. Multiple lesions often indicate a heavier tumor burden and may require combination chemotherapy and multimodal management.

---

Causes (Risk Factors) of Metastatic Spread

1. Vascular Invasion by Tumor Cells
   When choriocarcinoma cells invade blood vessels in the uterus or primary tumor site, they gain direct access to the bloodstream and can travel to distant organs.

2. High hCG Levels
   Excess production of hCG correlates with a large number of malignant trophoblasts, increasing the likelihood that some will break away and form metastases.

3. Delayed Diagnosis
   The longer the primary tumor remains untreated, the more opportunity cancer cells have to enter circulation and seed distant sites.

4. Deep Myometrial Invasion
   Tumors that grow deeply into the uterine muscle (myometrium) are more likely to breach blood vessels and metastasize.

5. Prior Molar Pregnancy
   A molar (hydatidiform) pregnancy, especially a complete mole, carries a higher risk of developing choriocarcinoma that can metastasize if not monitored closely.

6. Interval from Pregnancy to Diagnosis
   A long gap (more than 6–12 months) between the antecedent pregnancy and detection of choriocarcinoma is associated with a higher risk of metastatic disease.

7. High FIGO Prognostic Score
   The International Federation of Gynecology and Obstetrics (FIGO) score incorporates factors like age, antecedent pregnancy, and hCG levels; a score above 6 signals high-risk disease and more likely metastases.

8. Tumor Size Greater Than 5 cm
   Larger primary tumors shed more cells into the bloodstream, increasing metastatic potential.

9. Immune Evasion by Tumor Cells
   Changes in surface proteins (such as downregulation of HLA antigens) allow cancer cells to avoid detection and destruction by the immune system.

10. Molecular Mutations (e.g., p53)
    Genetic alterations that disrupt normal cell cycle control and apoptosis can enable tumor cells to survive in the circulation and colonize distant tissues.

11. Overexpression of Angiogenic Factors
    High levels of vascular endothelial growth factor (VEGF) promote new blood vessel formation around the tumor, facilitating invasion into the bloodstream.

12. Elevated Matrix Metalloproteinases (MMPs)
    MMP enzymes break down surrounding tissue barriers, allowing cancer cells to penetrate blood vessels.

13. Inflammatory Microenvironment
    Chronic inflammation in the uterus encourages cancer cell survival and mobility, enhancing metastatic spread.

14. Hypoxia within the Tumor
    Low oxygen areas stimulate cancer cells to adopt invasive behaviors and produce factors that aid metastasis.

15. Prior Incomplete Chemotherapy
    Sub-therapeutic or interrupted treatment can leave resistant tumor clones that are more aggressive and prone to metastasize.

16. Advanced Maternal Age
    Women over age 40 who develop choriocarcinoma often present with more aggressive, metastatic disease.

17. Non-White Ethnicity
    Certain populations may have a slightly elevated risk of aggressive choriocarcinoma, possibly due to genetic or socioeconomic factors.

18. Poor Nutritional Status
    Low protein levels and vitamin deficiencies can impair immunity and tissue integrity, indirectly aiding tumor spread.

19. Smoking
    Tobacco toxins promote DNA damage and impair blood vessel health, potentially facilitating tumor cell entry into circulation.

20. Family History of Abnormal Pregnancies
    Although rare, genetic predisposition to trophoblastic disease can increase the chance that any trophoblastic tumor will metastasize.

---

Symptoms of Metastatic Choriocarcinoma

1. Persistent Vaginal Bleeding
   Often the first sign, bleeding after any type of pregnancy should raise concern for trophoblastic disease and possible metastases.

2. Cough or Chest Pain
   Lung metastases irritate lung tissue, causing a persistent cough, chest discomfort, or even coughing up blood.

3. Shortness of Breath
   Multiple lung nodules or large pulmonary lesions reduce lung capacity, leading to breathlessness, especially on exertion.

4. Neurological Signs (Headache, Seizures)
   Brain metastases can cause increased intracranial pressure, resulting in headaches, seizures, or focal neurological deficits.

5. Abdominal Pain or Distension
   Liver metastases may stretch the liver capsule, causing right upper-quadrant pain or a sense of fullness.

6. Nausea and Vomiting
   Secondary to increased intracranial pressure from brain lesions or chemical irritation from liver metastases.

7. Fatigue and Weakness
   Cancer-related anemia and systemic illness drain energy, causing persistent tiredness.

8. Weight Loss
   Unintentional weight reduction reflects the metabolic demands of widespread disease.

9. Fever of Unknown Origin
   Tumor-related inflammation can produce low-grade fevers without infection.

10. Hematuria (Blood in Urine)
    Rare kidney metastases may cause bleeding into the urinary tract.

11. Melena or Hematochezia
    Intestinal metastases can ulcerate, leading to dark, tarry stools or visible blood.

12. Bone Pain
    Bone involvement causes localized pain, especially in the spine or pelvis.

13. Ocular Symptoms (Blurred Vision)
    Metastases to the eye or orbit can alter vision and cause eye discomfort.

14. Vaginal Nodules or Lesions
    Vaginal metastases may be visible on exam as small, friable nodules that bleed easily.

15. Neck Swelling
    Rare cervical lymph node involvement can present as painless neck lumps.

16. Menstrual Irregularities
    Metastatic hormone-producing tumors can disrupt normal menstrual cycles.

17. Polycythemia
    Tumor-produced erythropoietin in rare liver metastases can elevate red blood cells.

18. Jaundice
    Significant liver involvement may impair bile flow, leading to yellowing of skin and eyes.

19. Hypotension and Tachycardia
    Massive hemorrhage from metastatic sites can cause low blood pressure and fast heart rate.

20. Generalized Itching
    Paraneoplastic effects of hCG can occasionally trigger pruritus (itching) without a rash.

---

Diagnostic Tests

Physical Examination

1. Pelvic Palpation
   Checking the size and contour of the uterus to detect enlargement from residual tumor.

2. Lung Auscultation
   Listening for crackles or decreased breath sounds that may indicate pulmonary nodules.

3. Neurological Exam
   Assessing reflexes, strength, and coordination to detect brain involvement.

4. Abdominal Palpation
   Feeling for hepatomegaly or abdominal masses from liver metastases.

5. Skin Inspection
   Looking for nodules or discolorations suggestive of cutaneous metastases.

Manual Tests

6. Speculum Examination
   Visualizing the cervix and vagina for friable lesions.

7. Bimanual Pelvic Exam
   Palpating the uterus and adnexa to assess for masses or tenderness.

8. Rectal Exam
   Evaluating for lower vaginal or rectal wall involvement.

9. Neurological Coordination Tests
   Finger-to-nose and heel-to-shin maneuvers to detect cerebellar metastases.

10. Visual Field Testing
    Confrontation testing to identify visual deficits from ocular or brain lesions.

Laboratory and Pathological Tests

11. Serum β-hCG Level
    A hallmark test: elevated hCG confirms trophoblastic activity.

12. Complete Blood Count (CBC)
    Checking for anemia, leukocytosis, or thrombocytopenia from bleeding or marrow involvement.

13. Liver Function Tests (LFTs)
    Detecting elevated enzymes that suggest hepatic metastases.

14. Renal Function Tests
    Monitoring blood urea nitrogen and creatinine to evaluate kidney metastases or chemotherapy effects.

15. Coagulation Profile
    Assessing bleeding risk, since metastases can cause coagulopathy.

16. Thyroid Function Tests
    Rare choriocarcinoma cells can produce thyroid-stimulating hormone-like substances, affecting thyroid levels.

17. Tumor Marker Panel
    Checking lactate dehydrogenase (LDH) and other markers for germ cell tumor activity.

18. Histopathology of Uterine Curettage
    Microscopic confirmation of choriocarcinoma cells in endometrial tissue.

19. Immunohistochemistry
    Staining for hCG and cytokeratins to distinguish choriocarcinoma from other cancers.

20. Genetic Testing on Tumor Tissue
    Identifying chromosomal abnormalities that may guide prognosis.

Electrodiagnostic Tests

21. Electroencephalogram (EEG)
    Detecting seizure foci if neurological symptoms occur from brain metastases.

22. Nerve Conduction Studies
    Rarely indicated to evaluate neuropathy from paraneoplastic effects.

23. Electrocardiogram (ECG)
    Baseline heart rhythm check before chemotherapy; also to detect cardiac metastases.

24. Cardiac Stress Test
    In selected cases with suspected heart involvement.

25. Holter Monitoring
    For intermittent arrhythmias due to cardiac metastases.

Imaging Tests

26. Chest X-Ray
    First-line screen for lung nodules—often the first clue to pulmonary metastases.

27. Transvaginal Ultrasound
    Examining the uterus and adnexa for residual disease.

28. Pelvic MRI
    High-resolution imaging of uterine and vaginal involvement.

29. CT Scan of Chest, Abdomen, Pelvis
    Detailed mapping of metastatic lesions in lungs, liver, kidneys, and other organs.

30. Brain MRI
    Sensitive detection of small cerebral metastases.

31. PET-CT Scan
    Functional imaging to identify active metastases throughout the body.

32. Bone Scan
    Detects skeletal metastases not visible on plain X-rays.

33. Angiography
    Rarely used, but can localize vascular metastases before embolization.

34. Endoscopic Evaluation
    Gastroscopy or colonoscopy if GI bleeding suggests intestinal metastases.

35. Echocardiography
    Transthoracic or transesophageal echo to visualize cardiac metastases.

36. Renal Ultrasound
    Assessing kidney size and structure if renal metastases are suspected.

37. Chest CT Angiography
    Distinguishing tumor nodules from pulmonary embolism.

38. Bronchoscopy with Biopsy
    Direct sampling of pulmonary lesions when tissue confirmation is needed.

39. Stereotactic Brain Biopsy
    In select cases to confirm brain metastases histologically.

40. Vaginal Biopsy
    Sampling friable vaginal nodules to verify metastatic trophoblastic cells.

Non-Pharmacological Treatments

Evidence-based supportive and palliative interventions play an essential role in managing symptoms, improving function, and enhancing quality of life in patients with metastatic choriocarcinoma.

A. Physiotherapy & Electrotherapy Therapies

1. Transcutaneous Electrical Nerve Stimulation (TENS)
   Description: Low-voltage electrical currents delivered via skin electrodes.
   Purpose: Alleviate metastatic bone pain.
   Mechanism: Activates Aβ fibers to “gate” pain signals in the dorsal horn and stimulates endogenous endorphin release pmc.ncbi.nlm.nih.gov.

2. Ultrasound Therapy
   Description: High-frequency sound waves applied via a transducer.
   Purpose: Reduce soft tissue pain, enhance healing around metastatic lesions.
   Mechanism: Promotes local blood flow, reduces edema, and alters pain receptor activity pmc.ncbi.nlm.nih.gov.

3. Interferential Current Therapy
   Description: Two medium-frequency currents crossing in tissue.
   Purpose: Deep pain relief and muscle spasm reduction.
   Mechanism: Produces analgesia via gate control and increased circulation.

4. Hot/Cold Pack Therapy
   Description: Alternating thermotherapy and cryotherapy.
   Purpose: Manage pain and muscle tension around metastatic sites.
   Mechanism: Heat dilates vessels, reduces stiffness; cold constricts vessels, numbs nociceptors.

5. Manual Lymphatic Drainage
   Description: Gentle massage to stimulate lymph flow.
   Purpose: Reduce limb lymphedema from pelvic metastases or surgical lymphadenectomy.
   Mechanism: Enhances lymph clearance, reduces interstitial fluid.

6. Spinal Traction
   Description: Mechanical stretching of the spine.
   Purpose: Alleviate back pain from vertebral metastases.
   Mechanism: Decompresses intervertebral discs and facet joints.

7. Soft Tissue Mobilization
   Description: Hands-on kneading and stretching of muscles.
   Purpose: Relieve metastatic muscle pain and stiffness.
   Mechanism: Breaks adhesions, increases local circulation.

8. Low-Level Laser Therapy
   Description: Low-intensity laser applied to skin.
   Purpose: Decrease pain and promote tissue repair around superficial metastases.
   Mechanism: Modulates mitochondrial activity, reduces inflammatory mediators.

9. Electrical Muscle Stimulation (EMS)
   Description: Pulsed currents to evoke muscle contractions.
   Purpose: Prevent muscle atrophy in sedentary, metastatic patients.
   Mechanism: Induces muscle fiber recruitment and preserves strength.

10. Pulsed Electromagnetic Field Therapy
    Description: Time-varying magnetic fields applied externally.
    Purpose: Support bone health around osteolytic metastases.
    Mechanism: Stimulates osteoblast activity and modulates inflammation.

11. Iontophoresis
    Description: Electrical current to drive anti-inflammatory medications transdermally.
    Purpose: Local inflammation control over skin metastases.
    Mechanism: Facilitates drug penetration via ion movement.

12. Manual Therapy (Mobilizations)
    Description: Joint mobilizations by a therapist.
    Purpose: Improve range of motion when metastases impair function.
    Mechanism: Mechanical stretching of joint capsules reduces pain.

13. Trigger Point Therapy
    Description: Pressure applied to hyperirritable muscle spots.
    Purpose: Relieve referred pain from metastatic muscle involvement.
    Mechanism: Deactivates nociceptive trigger points.

14. Therapeutic Taping (Kinesio Tape)
    Description: Elastic tape applied to skin.
    Purpose: Support muscles and reduce pain around metastatic areas.
    Mechanism: Improves proprioception and lymphatic drainage.

15. Hydrotherapy
    Description: Exercises in warm water.
    Purpose: Gentle pain-free movement for deconditioned metastatic patients.
    Mechanism: Buoyancy reduces joint load; warmth relaxes muscles wjso.biomedcentral.com.

B. Exercise Therapies

1. Aerobic Walking Programs
   Description: Low-impact walking, 20–30 minutes, 3–5×/week.
   Purpose: Improve cardiovascular fitness, reduce fatigue.
   Mechanism: Enhances oxygen delivery and endorphin release wjso.biomedcentral.com.

2. Resistance Band Training
   Description: Light resistance exercises 2–3×/week.
   Purpose: Maintain muscle mass, support bone health.
   Mechanism: Mechanical loading stimulates osteoblasts and preserves strength wjso.biomedcentral.com.

3. Yoga for Cancer
   Description: Gentle, modified poses.
   Purpose: Enhance flexibility, reduce anxiety.
   Mechanism: Combines stretching with mindfulness to modulate stress response mskcc.org.

4. Pelvic Floor Exercises
   Description: Kegel exercises.
   Purpose: Strengthen pelvic muscles if pelvic metastases or surgical interventions occurred.
   Mechanism: Improves continence and core stability.

5. Inspiratory Muscle Training
   Description: Breathing against resistance.
   Purpose: Counteract respiratory muscle weakness from lung metastases or chemo.
   Mechanism: Strengthens diaphragm and accessory muscles.

C. Mind-Body Therapies

1. Mindfulness-Based Stress Reduction (MBSR)
   Description: Guided mindfulness meditation.
   Purpose: Alleviate anxiety, improve coping.
   Mechanism: Reduces hypothalamic–pituitary–adrenal (HPA) axis activation link.springer.com.

2. Cognitive Behavioral Therapy (CBT)
   Description: Structured psychotherapy.
   Purpose: Manage distress, insomnia, and maladaptive thoughts.
   Mechanism: Teaches cognitive restructuring to reduce negative affect.

3. Guided Imagery
   Description: Therapist-led visualization.
   Purpose: Reduce pain perception and nausea.
   Mechanism: Distraction and modulation of pain pathways.

4. Yoga Nidra
   Description: Deep relaxation technique.
   Purpose: Improve sleep quality and reduce fatigue.
   Mechanism: Elicits relaxation response via parasympathetic activation.

5. Supportive Group Therapy
   Description: Peer-led support groups.
   Purpose: Enhance emotional well-being and social support.
   Mechanism: Reduces isolation and fosters adaptive coping.

D. Educational Self-Management

1. Symptom Monitoring Training
   Description: Teaching patients to track pain, bleeding, and hCG levels.
   Purpose: Early detection of recurrence or complications.
   Mechanism: Empowers timely medical intervention.

2. Medication Adherence Education
   Description: Counseling on chemo schedules and side effect management.
   Purpose: Optimize treatment efficacy.
   Mechanism: Reduces missed doses and prevents resistance.

3. Nutrition Workshop
   Description: Guidance on high-protein, anti-inflammatory diets.
   Purpose: Support healing and immune function.
   Mechanism: Provides substrates for tissue repair.

4. Fatigue Management Program
   Description: Energy conservation techniques.
   Purpose: Improve activity tolerance.
   Mechanism: Balances rest and activity to prevent overexertion.

5. Advance Care Planning Sessions
   Description: Facilitated end-of-life discussions.
   Purpose: Clarify patients’ values and goals.
   Mechanism: Ensures care aligns with patient preferences and reduces anxiety.

---

Pharmacological Treatments

Below are the key therapeutic agents used in treating metastatic choriocarcinoma, including single-agent and multi-agent regimens, immunotherapies, and supportive drugs.

---

Dietary Molecular Supplements

Although direct evidence in choriocarcinoma is limited, the following agents show broad anti-cancer potential:

1. Curcumin (900 mg/day)
   Anti-inflammatory and pro-apoptotic via NF-κB and PI3K/Akt inhibition cancer.gov.

2. EGCG (400 mg/day)
   Anti-angiogenic by downregulating VEGF and MMP-9 pmc.ncbi.nlm.nih.gov.

3. Resveratrol (2.5 g/day)
   Modulates SIRT1, induces apoptosis; antioxidant pmc.ncbi.nlm.nih.govmedicalnewstoday.com.

4. Quercetin (500 mg/day)
   Inhibits PI3K/Akt, induces cell cycle arrest depts.washington.edu.

5. Sulforaphane (35 mg/day)
   Activates Nrf2/ARE, anti-oxidative and cytotoxic to cancer cells clinicaltrials.govmolmed.biomedcentral.com.

6. Melatonin (20 mg at bedtime)
   Immune modulation; ROS scavenging; oncostatic link.springer.commdpi.com.

7. Omega-3 fatty acids (1 g/day EPA + DHA)
   Anti-inflammatory via resolvins; supports appetite tandfonline.com.

8. Vitamin D₃ (4,000 IU/day)
   VDR-mediated differentiation, apoptosis induction news.harvard.edunature.com.

9. Selenium (200 μg/day)
   Glutathione peroxidase cofactor; DNA repair enhancement pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov.

10. Genistein (500 mg/day)
    Tyrosine kinase inhibition, NF-κB suppression link.springer.com.

---

Bone-Modifying & Regenerative Therapies

1. Zoledronic acid (4 mg IV q3–4 weeks)
   Bisphosphonate; inhibits FPP synthase in osteoclasts; reduces skeletal-related events pmc.ncbi.nlm.nih.govreference.medscape.com.

2. Pamidronate (90 mg IV over 2 h q3–4 weeks)
   Bisphosphonate; binds hydroxyapatite; inhibits osteoclasts accessdata.fda.govcancercareontario.ca.

3. Ibandronate (6 mg IV over 1–2 h q3–4 weeks or 50 mg PO daily)
   Bisphosphonate; FPP synthase inhibitor; pain palliation pmc.ncbi.nlm.nih.govgo.drugbank.com.

4. Denosumab (120 mg SC q4 weeks)
   RANKL mAb; prevents osteoclast formation; reduces bone turnover kosinmedj.org.

5. Hyaluronic acid (16 mg IA weekly × 3 weeks)
   Viscosupplement; restores synovial fluid viscosity; reduces pain reference.medscape.compmc.ncbi.nlm.nih.gov.

6. Platelet-Rich Plasma (PRP) (3 mL IA × 3 monthly injections)
   Concentrated growth factors; modulates inflammation, promotes tissue healing josr-online.biomedcentral.compmc.ncbi.nlm.nih.gov.

7. Mesenchymal Stem Cell Therapy (scaffold-based or IV 100–200 million cells)
   Differentiates to osteoblasts; secretes osteogenic factors; regenerates bone link.springer.comfrontiersin.org.

8. Romosozumab (210 mg SC monthly × 12 months)
   Sclerostin inhibitor; anabolic and antiresorptive; increases BMD go.drugbank.comaustralianprescriber.tg.org.au.

9. Recombinant BMP-2 (rhBMP-2) (1.5 mg/mL on collagen sponge)
   Osteoinductive; induces osteoblast differentiation via SMAD pathway accessdata.fda.govpmc.ncbi.nlm.nih.gov.

10. Bone Morphogenetic Protein-7 (rhBMP-7) (off-label in Europe)
    Similar osteoinductive action; supports fusion in spinal metastases .

2. How is disease monitored after treatment?
Weekly β-hCG until normal, then monthly for 6–12 months; imaging as indicated.

3. Can I become pregnant after choriocarcinoma?
Yes—up to 80% achieve at least one live birth after treatment; wait ≥6–12 months post-remission emedicine.medscape.com.

4. What are the main side effects of EMA-CO?
Myelosuppression, mucositis, alopecia, neuropathy, and potential secondary leukemia from etoposide.

5. Is fertility preserved?
Most patients retain ovarian function; fertility counseling and early referral for preservation if needed.

6. When is surgery indicated?
For solitary chemo-resistant metastases, life-threatening hemorrhage, or diagnostic uncertainty.

7. What supportive care is recommended?
Anti-emetics (ondansetron), G-CSF for neutropenia, pain management, nutritional support.

8. Are immunotherapies used?
Pembrolizumab shows promise in chemo-resistant cases (200 mg IV q3 weeks) england.nhs.uk.

9. How long is chemotherapy continued?
Continue until 3 consecutive normal β-hCGs; then 1–3 cycles consolidation.

10. Can non-pharmacological therapies help?
Yes—physiotherapy, exercise, mind-body, and educational strategies improve symptoms and QoL wjso.biomedcentral.comlink.springer.com.

11. What nutritional supplements are beneficial?
Omega-3s, vitamin D, curcumin, EGCG support immune and anti-cancer pathways.

12. How is bone health managed?
Bisphosphonates (zoledronate 4 mg IV q3–4 weeks) or denosumab SC q4 weeks reference.medscape.comkosinmedj.org.

13. What symptoms warrant immediate care?
Severe hemoptysis, neurologic deficits, acute abdominal pain, or signs of hypercalcemia.

14. How does psychosocial support help?
Reduces anxiety and depression, improves adherence, and enhances coping.

15. Are there clinical trials available?
Yes—many institutions offer trials in immunotherapy, targeted agents, and supportive care; ask your oncologist.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 01, 2025.